|
Powered by Cell Signaling Technology |
Site Information |
---|
EELAyLkkNHEEEIs SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 12291852 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
References | |
---|---|
Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44, 325-40
21906983 Curated Info |
|
Possemato A (2010) CST Curation Set: 9656; Year: 2010; Biosample/Treatment: cell line, HCT 116/MG132; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info |
|
Possemato A (2009) CST Curation Set: 8585; Year: 2010; Biosample/Treatment: cell line, PC3/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info |
|
Possemato A (2009) CST Curation Set: 8586; Year: 2010; Biosample/Treatment: cell line, PC3/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info |